Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $1,401,900.00 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Julie Cooke sold 10,000 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $140.19, for a total value of $1,401,900.00. Following the sale, the insider now directly owns 18,202 shares of the company’s stock, valued at approximately $2,551,738.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Neurocrine Biosciences Trading Down 1.9 %

NASDAQ:NBIX traded down $2.62 during mid-day trading on Tuesday, reaching $137.49. The company’s stock had a trading volume of 728,623 shares, compared to its average volume of 836,198. The firm’s fifty day moving average price is $137.42 and its two-hundred day moving average price is $136.06. The stock has a market cap of $13.84 billion, a P/E ratio of 37.88 and a beta of 0.37. Neurocrine Biosciences, Inc. has a 12-month low of $93.28 and a 12-month high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, May 1st. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.04 by ($0.62). The company had revenue of $515.30 million during the quarter, compared to analysts’ expectations of $512.21 million. Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. Analysts predict that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current fiscal year.

Institutional Trading of Neurocrine Biosciences

A number of hedge funds have recently bought and sold shares of NBIX. First Horizon Advisors Inc. boosted its position in Neurocrine Biosciences by 10.5% in the fourth quarter. First Horizon Advisors Inc. now owns 782 shares of the company’s stock worth $103,000 after purchasing an additional 74 shares during the last quarter. Quadrant Capital Group LLC lifted its stake in shares of Neurocrine Biosciences by 3.9% in the 4th quarter. Quadrant Capital Group LLC now owns 2,075 shares of the company’s stock worth $273,000 after purchasing an additional 78 shares during the period. Envestnet Portfolio Solutions Inc. boosted its holdings in shares of Neurocrine Biosciences by 3.2% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,530 shares of the company’s stock worth $333,000 after buying an additional 78 shares during the last quarter. Sunbelt Securities Inc. grew its position in Neurocrine Biosciences by 34.3% during the third quarter. Sunbelt Securities Inc. now owns 325 shares of the company’s stock valued at $37,000 after buying an additional 83 shares during the period. Finally, Commonwealth Equity Services LLC increased its holdings in Neurocrine Biosciences by 0.6% during the first quarter. Commonwealth Equity Services LLC now owns 13,941 shares of the company’s stock valued at $1,923,000 after buying an additional 84 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on NBIX shares. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research report on Wednesday, May 1st. Oppenheimer raised their target price on Neurocrine Biosciences from $200.00 to $216.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. JPMorgan Chase & Co. upped their price target on Neurocrine Biosciences from $148.00 to $158.00 and gave the company an “overweight” rating in a research report on Wednesday, March 20th. Wells Fargo & Company upgraded Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $140.00 to $170.00 in a research report on Wednesday, April 24th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $152.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, May 29th. Six investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $152.00.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.